| Survivors, n = 58 | Non-survivors, n = 25 | p | |
---|---|---|---|---|
HLA-DR expression (antibodies/cell), median (IQR) | Sample A (days 1–2)a | 7495 (4672, 15,824) n = 51 | 6971 (2525, 9162) n = 22 | 0.14 |
Sample B (days 3–4)a | 11351 (4316, 18,417) n = 43 | 5895 (2900, 10,388) n = 16 | 0.04 | |
Sample C (days 6–8)a | 14470 (7656, 17,906) n = 18 | 6195 (3721, 9662) n = 10 | 0.002 | |
Δ Sample A to B | 434 (-1710, 2921) | -630 (-1795, 626) | 0.34 | |
Δ Sample A to C | 1662 (-2645, 8118) | 810 (-3382, 3507) | 0.04 | |
LPS-induced TNF-ɑ production (pg/ml), median (IQR) | Sample A (days 1–2)a | 204 (73, 411) n = 50 | 176 (80, 396) n = 22 | 0.87 |
Sample B (days 3–4)a | 209 (101, 358) n = 40 | 232 (106, 716) n = 16 | 0.56 | |
Sample C (days 6–8)a | 320 (111, 414) n = 17 | 225 (29, 358) n = 10 | 0.52 | |
Δ Sample A to B | 0 (-130, 54) | 20 (-23, 89) | 0.27 | |
Δ Sample A to C | 16 (-112, 85) | 29 (-85, 141) | 0.56 |